301. Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T
- Author
-
Þ Martin Halle, Alexander Hapfelmeier, Þ Michael Rasper, Otto Zelger, Moritz Wildgruber, Ernst J. Rummeny, Armin Huber, Hans-Henning Eckstein, and Thomas Stadlbauer
- Subjects
Gadolinium DTPA ,Male ,Gadolinium ,Myocardial Infarction ,chemistry.chemical_element ,Contrast Media ,Inversion recovery ,Signal-To-Noise Ratio ,Gadobutrol ,medicine ,Organometallic Compounds ,Humans ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,cardiovascular diseases ,Prospective Studies ,GADOBENATE DIMEGLUMINE ,Aged ,Chronic myocardial infarction ,medicine.diagnostic_test ,business.industry ,Myocardium ,Reproducibility of Results ,Magnetic resonance imaging ,General Medicine ,Original Articles ,contrast agent ,medicine.disease ,Image Enhancement ,Crossover study ,Magnetic Resonance Imaging ,chemistry ,late gadolinium enhancement ,cardiovascular system ,Female ,Nuclear medicine ,business ,medicine.drug - Abstract
Objectives The aim of this study was to compare the contrast-to-noise ratio (CNR) values of infarct and remote myocardium as well as infarct and blood after application of 0.1 mmol/kg gadobutrol and 0.1 mmol/kg gadobenate dimeglumine on late gadolinium enhancement magnetic resonance (MR) images. Material and Methods The study was a prospective randomized controlled clinical study. After informed consent was obtained, 20 patients (12 men, 8 women; mean age, 67 ± 11 years) with known chronic myocardial infarction were included for an intraindividual comparison of a single-dose gadobutrol and a single-dose gadobenate dimeglumine. Two MR imaging examinations were performed within a period of 28 days in a crossover design. Late gadolinium enhancement imaging was performed 10 minutes after gadolinium administration using a 2-dimensional phase-sensitive inversion recovery gradient echo sequence at 3 T. Infarct size, signal intensities (SIs), signal-to-noise ratio, and CNR were determined on phase-sensitive MR images. Values for CNR were calculated as CNRinfarct/myocardium = (SIinfarct − SImyocardium)/SDnoise and CNRinfarct/blood = (SIinfarct − SIblood)/SDnoise. In addition, the areas of myocardial infarction were determined on single slices. The entire infarct volumes were calculated by adding the areas with hyperenhancement multiplied by the slice thickness. Results Late gadolinium enhancement was present in all patients. Median values of the infarct area, infarct volume, and transmurality for gadobutrol and gadobenate dimeglumine showed good to excellent concordance (rc = 0.85, rc = 0.95, and rc = 0.71, respectively). The mean signal-to-noise ratio values for infarct, remote myocardium, and ventricular blood were 18.6 ± 6.5, 4.1 ± 3.7, and 14.6 ± 7.5, respectively, for gadobutrol and 18.8 ± 8.9, 4.9 ± 4.5, and 17.8 ± 10.1, respectively, for gadobenate dimeglumine (P = 0.93, P = 0.48, and P = 0.149, respectively). The mean values of CNRinfarct/myocardium and CNRinfarct/blood were 14.5 ± 5.9 and 4.0 ± 4.6, respectively, for gadobutrol and 13.9 ± 6.1 and 0.9 ± 4.5, respectively, for gadobenate dimeglumine (P = 0.69 and P = 0.02, respectively). Conclusion Both gadobutrol and gadobenate dimeglumine allow for successful late gadolinium enhancement imaging of chronic myocardial infarction after a single-dose application (0.1 mmol/kg) at 3 T. Gadobutrol provides a higher CNR between infarct and blood. The CNRs between infarct and normal myocardium, infarct size, and transmural extent were similar for both contrast agents.